Fundraisings and IPOs

* On November 18, 2013, Cytos Biotechnology has announced the completion of a financing transaction that raised a total of CHF 24.3 million by selling 8.1 million shares at a price of CHF 3.00 per share. The rights offering was oversubscribed and share allocations included the use of authorized capital. International institutional investors as well as other shareholders have invested CHF 10.2 million. The group of institutional and strategic shareholders, Abingworth, Amgen, venBio and Aisling, initially committed to invest CHF 9 million. Amgen further increased its participation by CHF 5.1 million, leading to a total investment by this group of CHF 14.1 million.

This financing transaction consisted of a rights offering of 6’303’215 shares to existing shareholders whereby those rights not taken up were allocated by the Board of Directors to other shareholders or new investors. In addition, further 1’810’630 shares were placed out of the authorized share capital. The financing of CHF 24.3 million is in the form of registered shares issued by Cytos at CHF 3.00 per share and results in an increase of the issued share capital by a total of 8’113’845 new shares of Cytos.

* On November 5, 2013, Cytos Biotechnology has announced the terms for a capital increase in the form of a rights offering as follows: Shares are issued for CHF 3.00 and 32 existing shares entitle to subscribe for 9 new registered shares. Cytos shareholders will receive additional information regarding the exercise of the subscription rights via their bank or broker in the coming days.

As previously announced, the group of institutional and strategic shareholders that invested in the Company in 2012, namely Abingworth, venBio, Aisling and Amgen, will increase their investment by CHF 9 million as part of the rights offering. The Company’s board of directors intends to make available to new investors any shares that are not subscribed by the current shareholders in the rights offering.